Inovio Pharmaceuticals, Inc. - Laporan Laba Rugi (TTM)

Inovio Pharmaceuticals, Inc.

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Inovio Pharmaceuticals, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 2 7 6 6 7 2 2 2 11 10 10 10 1 1 1 1 0 0 0 0
Change (%) 251.22 -12.90 0.09 0.86 -72.76 -9.69 31.92 419.17 -6.51 -0.82 -5.49 -91.12 -2.58 -13.82 -17.46 -65.63 7.05 30.01 -35.59
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 88 94 114 163 183 249 266 252 238 188 162 127 110 85 75 77 82 76 71 62
Change (%) 7.04 21.15 42.42 12.69 36.02 6.79 -5.39 -5.56 -21.10 -13.75 -21.44 -13.83 -22.70 -10.94 1.76 6.79 -7.75 -6.38 -12.10
% of Revenue 4,172.58 1,271.66 1,768.82 2,516.92 2,812.12 14,043.62 16,607.76 11,910.95 2,166.67 1,828.55 1,590.16 1,321.69 12,828.54 10,179.22 10,519.16 12,968.89 40,298.50 34,727.10 25,008.02 34,129.85
Gross Operating Profit -86 -87 -108 -156 -177 -247 -265 -250 -227 -177 -152 -118 -109 -84 -75 -76 -82 -75 -71 -62
Change (%) 1.04 24.06 44.95 13.18 40.03 6.91 -5.61 -9.16 -21.80 -14.50 -22.51 -7.50 -22.86 -10.91 1.95 7.36 -7.79 -6.48 -12.01
% of Revenue -4,072.58 -1,171.66 -1,668.82 -2,416.92 -2,712.12 -13,943.62 -16,507.76 -11,810.95 -2,066.67 -1,728.55 -1,490.16 -1,221.69 -12,728.54 -10,079.22 -10,419.16 -12,868.89 -40,198.50 -34,627.10 -24,908.02 -34,029.85
SG&A 37 37 44 45 48 54 56 92 90 76 73 39 37 43 41 36 40 37 35 34
Change (%) -0.21 17.27 3.65 6.73 11.24 3.86 64.11 -1.45 -15.62 -4.15 -46.33 -4.85 15.00 -5.18 -10.85 9.35 -6.67 -4.18 -4.65
% of Revenue 1,768.94 502.59 676.69 700.78 741.55 3,028.71 3,483.13 4,333.15 822.50 742.38 717.44 407.38 4,366.35 5,154.04 5,670.69 6,124.73 19,486.74 16,989.81 12,522.17 18,538.79
R&D
Change (%)
% of Revenue
OpEx 125 131 158 208 232 303 322 343 328 264 235 166 147 128 116 113 122 113 106 96
Change (%) 4.88 20.05 31.69 11.39 30.85 6.27 6.66 -4.46 -19.59 -10.98 -29.18 -11.71 -13.13 -9.00 -2.66 7.61 -7.40 -5.66 -9.61
% of Revenue 5,941.53 1,774.25 2,445.51 3,217.70 3,553.67 17,072.34 20,090.89 16,244.10 2,989.17 2,570.93 2,307.60 1,729.07 17,194.89 15,333.25 16,189.85 19,093.62 59,785.26 51,716.92 37,530.19 52,668.64
Operating Income -123 -124 -151 -201 -225 -301 -320 -341 -317 -254 -225 -157 -146 -127 -115 -112 -121 -112 -106 -96
Change (%) 0.66 22.02 33.04 11.73 33.85 6.37 6.53 -7.09 -20.04 -11.39 -30.25 -6.84 -13.19 -8.97 -2.57 8.00 -7.42 -5.72 -9.54
% of Revenue -5,841.53 -1,674.25 -2,345.51 -3,117.70 -3,453.67 -16,972.34 -19,990.89 -16,144.10 -2,889.17 -2,470.93 -2,207.60 -1,629.07 -17,094.89 -15,233.25 -16,089.85 -18,993.63 -59,685.22 -51,616.90 -37,430.19 -52,568.64
Interest Expense -10 -9 -6 -4 -3 -2 -2 -2 -1 -1 -1 -1 -1 -1 -1 -1 -0 -0 0 0
Change (%) -15.54 -26.32 -37.12 -37.39 -23.28 -10.30 -8.82 -10.29 -11.74 -0.00 -0.00 -0.00 -2.49 -11.09 -28.84 -40.52 -61.35 -100.00 NaN
% of Revenue -488.28 -117.42 -99.33 -62.41 -38.74 -109.11 -108.37 -74.90 -12.94 -12.22 -12.32 -13.04 -146.83 -146.97 -151.61 -130.71 -226.22 -81.67 0.00 0.00
Net Income -180 -166 -188 -142 -221 -304 -328 -355 -332 -280 -241 -168 -165 -135 -125 -122 -113 -107 -96 -88
Change (%) -7.41 13.14 -24.73 55.99 37.37 8.12 8.03 -6.31 -15.79 -13.73 -30.23 -2.29 -17.90 -7.53 -2.64 -7.21 -4.98 -10.05 -9.04
% of Revenue -8,517.72 -2,245.40 -2,916.66 -2,193.40 -3,392.29 -17,109.87 -20,485.92 -16,775.80 -3,027.34 -2,726.67 -2,371.69 -1,750.89 -19,270.74 -16,239.88 -17,423.46 -20,552.31 -55,491.09 -49,254.26 -34,079.58 -48,131.36

Source: Capital IQ

Other Listings
MX:INO
GB:0A43
DE:GBM
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista